Valuation: NetraMark Holdings Inc.

Market Cap 55.83M 40.01M 35.84M 32.96M 29.87M 3.8B 56.88M 393M 158M 2B 150M 147M 6.3B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 55.83M 40.01M 35.84M 32.96M 29.87M 3.8B 56.88M 393M 158M 2B 150M 147M 6.3B EV / Sales 2026 *
139x
EV / Sales 2027 * -
Free-Float
89.17%
Yield 2026 *
-
Yield 2027 * -
10/09 NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models CI
02/09 Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors CI
15/08 NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 CI
10/07 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
09/07 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
30/06 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
29/06 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
15/05 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
08/05 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
04/05 NetraMark Holdings Inc. Announces Executive Changes CI
22/04 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
20/04 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
10/04 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
1 day+1.72%
1 week+13.46%
1 month-18.06%
3 months-26.25%
6 months-36.56%
Current year-46.36%
1 week 0.54
Extreme 0.54
0.6
1 month 0.48
Extreme 0.48
0.72
Current year 0.48
Extreme 0.48
1.28
1 year 0.48
Extreme 0.48
1.29
3 years 0.16
Extreme 0.155
1.8
5 years 0.15
Extreme 0.15
1.97
10 years 0.15
Extreme 0.15
3.17
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Date Insider Type Main position Quantity % Market Cap. Importance
23/9/26 Buy

Chairman

10,000 0.0108%
23/9/26 Buy

Chairman

25,000 0.0270%
23/9/26 Buy

Chairman

25,000 0.0270%
Change 5-day change 1-year change 3-year change Capi.($)
+1.72%+13.46%-51.64%+63.89% 40.01M
-1.55%-0.50%+0.79%+54.36% 3,876B
-6.27%-6.42%-8.16%+1,143.99% 442B
-6.37%+3.57%-50.24%+26.37% 396B
-3.86%-3.86%+66.12%+201.10% 300B
+1.12%-1.47%-5.88%+66.68% 272B
-4.10%-2.77%+84.48%+466.68% 257B
-4.15%-33.87%-42.82%-9.67% 109B
-2.17%-24.40%+57.45%+138.03% 99.98B
+0.85%-5.15%-26.47%-52.97% 97.39B
Average -2.48%-6.14%+2.36%+209.85% 584.97B
Weighted average by Cap. -2.36%-2.10%+3.07%+159.53%

Financials

2026 *2027 *
Net sales 401K 287K 257K 237K 214K 27.28M 408K 2.82M 1.13M 14.35M 1.08M 1.06M 45.26M -
Net income - -
Net Debt - -
Projected Income Statement - Annual - NetraMark Holdings Inc.
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
30/10/26 CAD 0.5900 +1.72% 15,204
28/10/26 CAD 0.5800 +5.45% 32,300
27/10/26 CAD 0.5500 +5.77% 7,601
23/10/26 CAD 0.5200 +4.00% 134,300

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - NetraMark Holdings Inc.
  1. Stock Market
  2. Stocks
  3. AIAI Stock